Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.

Yousuf Zafar, MD, on the Financial Burden of Cancer Care

Yousuf Zafar, MD, of Duke Cancer Institute, summarizes his educational lecture on the financial toxicities of treatment and the need to focus on both short- and long-term interventions to reduce the burden on patients.

Colorectal Cancer

Alan P. Venook, MD, and John Marshall, MD, on Metastatic Colorectal Cancer: Analysis of CALGB-SWOG 80405

Alan Venook, MD, of the University of California, San Francisco, and John Marshall, MD, of the Lombardi Cancer Center at Georgetown University, discuss the impact of primary tumor location on overall survival and progression-free survival in patients with advanced disease (Abstract 3504).

Skin Cancer

Anthony J. Olszanski, RPh, MD, and Michael A. Postow, MD, on Results From the CheckMate 067 Melanoma Trial

Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Michael A. Postow, MD, of Memorial Sloan Kettering Cancer Center, discuss findings from this phase III trial of nivolumab combined with ipilimumab in treatment-naive patients with advanced disease (Abstract 9505).

Breast Cancer

Gynecologic Cancers

Lisa A. Carey, MD, and Tuya Pal, MD, on BRCA Carriers: The Disparities in Management

Lisa A. Carey, MD, of the University of North Carolina, and Tuya Pal, MD, of H. Lee Moffitt Cancer Center & Research Institute, discuss the racial disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors (Abstract LBA1504).

Bladder Cancer

Jonathan E. Rosenberg, MD, and Toni K. Choueiri, MD, on Bladder Cancer: Mutation Burden and Atezolizumab

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discuss mutation burden—its role in response to treatment with PD-L1 immunotherapy and its impact on progression-free survival and overall survival, as well as the link between intrinsic expression subtypes and treatment outcome with atezolizumab (Abstract 104).

Apr

Today In Oncology

Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

Related Videos

Yousuf Zafar, MD, on the Financial Burden of Cancer Care

Alan P. Venook, MD, and John Marshall, MD, on Metastatic Colorectal Cancer: Analysis of CALGB-SWOG 80405

Anthony J. Olszanski, RPh, MD, and Michael A. Postow, MD, on Results From the CheckMate 067 Melanoma Trial

Lisa A. Carey, MD, and Tuya Pal, MD, on BRCA Carriers: The Disparities in Management

Jonathan E. Rosenberg, MD, and Toni K. Choueiri, MD, on Bladder Cancer: Mutation Burden and Atezolizumab

Fullerene Cream vs Trolamine Cream in Reducing Acute Radiation Dermatitis From Radiation Therapy for Head and Neck Cancer

Skin Fluorescent Imaging Shows High Sensitivity, Specificity for Discriminating Melanoma Lesions

NCCN 2026 Annual Conference Prepares Cancer Care Providers Worldwide for Healing the Whole Patient

Tanning Bed Exposure and Melanoma Risks

AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation